Teriparatide

Overview

Teriparatide, marketed as Forteo, is a recombinant form of the first 34 amino acids of human parathyroid hormone, written as PTH(1-34). This fragment retains the biologically active portion of the full hormone. Teriparatide is FDA-approved for the treatment of osteoporosis in people at high risk of fracture, including postmenopausal women, certain men, and patients whose osteoporosis is caused by long-term glucocorticoid (steroid) use.

What makes teriparatide notable is that it is an anabolic agent, meaning it actively builds new bone, in contrast to the more common antiresorptive drugs such as bisphosphonates, which work mainly by slowing bone breakdown. This distinction matters for patients with severe osteoporosis who need to gain bone mass rather than simply preserve it.

The drug is given as a once-daily subcutaneous injection, typically via a multi-dose pen device. The intermittent, daily dosing pattern is central to how it works. Because of cost, the injection requirement, and specific safety considerations, teriparatide is generally reserved for patients at substantial fracture risk rather than used as a first-line treatment for everyone with low bone density.

How it works

Parathyroid hormone has a paradoxical relationship with bone that depends entirely on the pattern of exposure. When PTH levels are continuously elevated, as in the disease hyperparathyroidism, the net effect is bone loss. However, when the hormone is delivered in brief, intermittent pulses, as with a single daily injection, the balance shifts toward bone formation. Teriparatide exploits this intermittent dosing to favor building over breakdown.

Mechanistically, teriparatide stimulates osteoblasts, the cells responsible for laying down new bone matrix. It appears to increase the number and activity of these bone-forming cells and to reduce their programmed death, tipping the remodeling balance toward net gain. Early in treatment, formation outpaces resorption, producing a window of particularly favorable bone building sometimes described as the anabolic window.

The result is increased bone mineral density, improved bone microarchitecture, and greater bone strength, which translate into reduced fracture risk. Because the daily pulse is essential to this effect, continuous exposure would undermine the benefit. This pulse-dependent biology explains why teriparatide is dosed once daily and why its anabolic action is fundamentally different from drugs that simply slow the removal of existing bone.

Clinical evidence

The pivotal evidence for teriparatide came from a large randomized, placebo-controlled trial in postmenopausal women with osteoporosis and prior vertebral fractures. Treatment significantly reduced the risk of new vertebral and nonvertebral fractures and increased bone mineral density at the spine and hip. These findings established teriparatide as an effective anabolic option for high-risk patients and supported its approval.

Subsequent studies examined its use in men with osteoporosis and in glucocorticoid-induced osteoporosis, where it also improved bone density, and in the latter setting compared favorably with an antiresorptive comparator on density and fracture outcomes. Research has likewise explored treatment sequencing, since the gains from teriparatide can be lost after stopping unless followed by an antiresorptive agent to preserve the newly built bone.

Because of a finding of bone tumors (osteosarcoma) in rats given high doses over much of their lifespan, clinical use has historically been limited to a defined treatment course, and long-term human surveillance has been an important part of the evidence base. Reassuringly, post-marketing monitoring has not shown the rat finding to translate into a comparable human signal, though caution and defined treatment durations remain standard.

Dosing & side effects

This guide does not provide dosing figures. Teriparatide is prescribed by clinicians and self-administered as a once-daily subcutaneous injection using a pen device, with treatment duration limited according to labeling and guidelines. The total lifetime course is capped, and therapy is typically followed by an antiresorptive medication to maintain the bone gained.

Teriparatide previously carried a boxed warning about osteosarcoma, a type of bone cancer, based on the rat studies described above; this warning has since been removed in light of accumulated human safety data, though it is still generally avoided in people at increased baseline risk of bone tumors, such as those with Paget's disease, prior skeletal radiation, or unexplained elevations in alkaline phosphatase.

Common side effects include nausea, dizziness, leg cramps, and headache. Some patients experience a transient rise in blood calcium after injection, and orthostatic hypotension, a drop in blood pressure on standing, can occur particularly with early doses, so initial injections are sometimes taken in a position where the patient can sit or lie down. As with any injectable, injection-site reactions may occur. Decisions about candidacy, duration, and follow-on therapy belong to a treating clinician.

Legal status

Teriparatide is an FDA-approved prescription medication in the United States, originally marketed as Forteo, and is approved in many other countries for the treatment of osteoporosis at high fracture risk. Following patent expiration, biosimilar and generic versions of teriparatide have become available in various markets, broadening access while remaining prescription-only products.

As a prescription pharmaceutical, teriparatide can only be obtained through a licensed healthcare provider and dispensed by a pharmacy. It is not a controlled substance. Its use is appropriately guided by clinical criteria, including fracture risk assessment, treatment-duration limits, and follow-on therapy planning, all of which require medical oversight.

Approval status and the availability of brand, biosimilar, and generic versions vary by country. Patients should rely solely on properly prescribed, pharmacy-dispensed product, which is subject to manufacturing and quality oversight. Material offered through research-chemical or other unregulated channels would fall outside lawful medical use and raises concerns about purity, potency, and sterility. Anyone considering teriparatide should discuss it with a qualified clinician who can determine whether an anabolic agent is appropriate and supervise the defined course of treatment.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. Peer-reviewed study
2. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human PTH(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003. Peer-reviewed study
3. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015. Peer-reviewed study
4. Li M, Ge Z, Zhang B, et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024. Peer-reviewed study
5. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004. Peer-reviewed study
6. Yuan F, Peng W, Yang C, et al. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019. Peer-reviewed study